# Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Source: https://onco.cc/trials/nct05236946/  
OnCo record `nct05236946` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Tata Memorial Hospital, now recruiting.

## Summary

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT is a phase 3, randomised interventional study registered as NCT05236946 by Tata Memorial Hospital, with a registry enrolment figure of 190 participants, started 2020-11-10 and due to reach its primary completion in 2025-12. Interventions recorded: Stereotactic radiosurgery/whole brain radiotherapy; Tyrosine kinase inhibitor. Conditions listed: Asymptomatic Brain Metastases; Driver Mutation Positive Non-small Cell Lung Cancer. Primary outcome: Intracranial progression free survival at 24 months. Lung eligibility wording from the registry: "Patients with pathologically proven diagnosis of NSCLC". Sites: India. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05236946
- Phase: 3
- Setting: Observation or Upfront Cranial RT in Oncogene Driver Mutated NSCLC With Asymptomatic Brain Metastases: A Phase III Randomized Controlled Trial
- Sponsor: Tata Memorial Hospital
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT05236946: https://clinicaltrials.gov/study/NCT05236946

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05236946.json